Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleCrunchbase News

Beyond Secondaries: Turbine Wants To Unlock Liquidity For Venture LPs

View original at news.crunchbase.com
Crunchbase News - Funding Ma Title: Beyond Secondaries: Turbine Wants To Unlock Liquidity For Venture LPs Date: 2026-02-24 12:00 Source: https://news.crunchbase.com/venture/beyond-secondaries-turbine-unlock-liquidity-lps-hurst/ <p>As a venture partner with <a href="https://www.crunchbase.com/organization/ttv-capital">T…
Opening lines of the source · Crunchbase News · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Should SpaceX reach IPO in 2026, it will be 24 years old

    80% confidence
  • Turbine's loans are relatively low LTV but high impact, as they empower borrowers to activate leverage in a previously illiquid arena

    80% confidence
  • A typical Turbine borrower is a family office with tens of millions in wealth spread across multiple asset classes

    80% confidence
  • Banks are built to lend against profitable, established businesses with cash flow to repay debt, not to properly value 15 to 20 pre-profitable companies from a venture portfolio

    80% confidence
  • LP positions are likely to trade lower than single-company stock secondaries due to attached fee structures

    80% confidence
  • If VC firms intend to continue raising new funds every three years, they need to provide their LPs with tools to bridge the liquidity gap

    80% confidence
  • In the absence of earlier company exits, the market needs other solutions to bridge the gap, and credit has a clear role to play in empowering investors to recycle capital

    80% confidence
  • The lack of significant returns from company exits means fewer dollars for LPs to recycle into new funds

    80% confidence
  • Venture secondary sales started to require significant discounts around 2022 timeframe, making secondaries less appealing for investors who could hold

    80% confidence
  • Companies have strong options available to stay private longer (if not forever), and the IPO hurdle is higher than ever before

    80% confidence
  • Limited partners suffered from the denominator effect where their public market accounts and real estate shrank in value, causing venture investments to represent a higher percentage of wealth than intended

    80% confidence
  • If a venture position is marked at 2.0x, the seller may be lucky to get their principal back in a secondary sale

    80% confidence
  • Turbine's debt is incredibly attractive relative to other credit products that banks and insurance companies are buying, such as credit card bonds and used-car debt

    80% confidence
  • Companies that went public in 2025 were a median age of 13 years old, up from a median age of 10 years in 2018

    80% confidence
  • VCs are not against LPs seeking credit backed by their positions, but they are against gigantic legal bills and heavy diligence from lenders designed to see less value in early-stage companies

    80% confidence
  • VCs were hesitant to call capital and were not actively investing at a time when valuations had reset after 2022

    80% confidence
  • Founders with excellent products and progress were struggling to raise funds to finish the job after the 2022 reset

    80% confidence
  • Single-company stock positions may clear at a 30%-60% discount to the company's last valuation in secondary sales, except for elite startups which command premiums

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com